Hiv-1 env fragment fusion protein
CA 2071858 A1 · Owner: Shafferman, Avigdor · Inventors: Shafferman, Avigdor; Shafferman, Avigdor
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Highly conserved polypeptide sequences derived from gp4l and gp 120, preferably from eleven to twenty-one amino acids in length are joined (for example, via DNA recombinant techniques) to a non-HIV protein or polypeptide sequence comprising an amino-acid sequence not naturally encoded by the HIV genome thereby forming a, fusion protein. Such fusion proteins possess attributes that make them suitable for use in the diagnosis treatment and prevention , of HIV infection.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 13, 1990. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 13, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 13, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.